查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830978

消融設備市場

Ablation Device Market
出版日期: | 出版商: The Insight Partners | 英文 185 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

2024 年消融設備市場價值為 97.9 億美元，預計到 2031 年將達到 173.8 億美元，2025 年至 2031 年的複合年成長率預計為 8.5%。

市場洞察與分析師觀點：消融術是指透過手術切除器官、結構或部分組織。消融設備利用熱量（通常由射頻、射頻能量或雷射產生）或極冷溫度來誘發輕微燒傷。消融設備市場的成長主要得益於慢性病發病率的上升、老齡人口的增加以及人們對微創手術日益成長的偏好。然而，替代治療方案和療法的蓬勃發展也對市場擴張構成了挑戰。

成長動力與限制因素：癌症、心血管疾病和呼吸系統疾病等慢性疾病的發生率不斷上升，推動了全球消融設備市場的發展。消融手術為腫瘤消融、心律不整和肺部疾病等各種疾病提供了有效的治療方案。世界衛生組織 (WHO) 報告稱，非傳染性疾病 (NCD) 每年在全球造成 4,100 萬人死亡。心血管疾病是 NCD 死亡的主要原因，每年奪走 1,790 萬人的生命，其次是癌症（930 萬人）、慢性呼吸道疾病（410 萬人）和糖尿病（200 萬人，包括與糖尿病相關的腎臟病死亡）。此外，美國國家癌症研究所 (NCI) 指出，癌症正日益成為全球健康問題。 2020 年，全球報告了超過 1,930 萬例新發癌症病例，導致約 1,000 萬人死於癌症。世界衛生組織預測，到2040年，每年將新增2,890萬例癌症病例，約1,620萬人死於癌症。慢性病負擔的不斷加重以及對治療方案的需求正在推動對消融設備的需求。

此外，老化是慢性疾病（尤其是心血管疾病和癌症）的重要風險因素。國際抗癌聯盟（UICC）指出，老化會顯著增加癌症風險，老年人的癌症發生率更高。世界衛生組織估計，2015 年至 2050 年間，全球 60 歲以上人口比例將幾乎加倍，從 12% 增加到 22%。 NCBI 於 2023 年 1 月發布的一項研究預測，到 2050 年，美國 50 歲及以上人口數量將從 2020 年的 1.3725 億增至 2.2113 億。預計 50 歲及以上人口將至少患一種慢性病，預測顯示將從 2020 年的 7,152 萬人增加 99.5% 至 2050 年的 1.4266 億。此外，預計到 2050 年將有約 1,400 萬人患有多種疾病。消融手術為老年人提供了微創治療選擇，但他們可能面臨更高的手術風險。因此，老年人口的成長加上慢性病盛行率的上升推動了消融設備市場的擴張。

然而，消融技術面臨替代治療方案的競爭，包括外科手術、放射療法、全身性藥物治療和其他微創技術。醫療保健提供者可能會根據療效、安全性、患者資格、成本效益或資源可用性等因素，根據所治療的特定病症選擇替代治療方式。替代治療方案的存在和偏好可能會限制消融設備的採用和使用。例如，由於公眾認知度高、發展中國家先進療法的採用有限以及外科醫生不願放棄傳統療法，手術、化療和放射療法等傳統癌症治療方法往往更受青睞。因此，這些因素阻礙了消融設備市場的成長。

策略洞察報告細分和範圍：全球消融設備市場按設備類型、應用和最終用戶進行分類。就設備類型而言，市場細分為射頻設備、雷射/光消融、超音波設備、冷凍消融設備及其他。依應用，消融設備市場分為癌症治療、心血管疾病治療、眼科治療、婦科治療、泌尿科治療、美容手術等。就最終用戶而言，市場細分為醫院和診所、門診手術中心及其他。從地理上看，消融設備市場分為北美（美國、加拿大和墨西哥）、歐洲（德國、法國、義大利、英國、俄羅斯和歐洲其他地區）、亞太地區（澳洲、中國、日本、印度、韓國和亞太其他地區）、中東和非洲（南非、沙烏地阿拉伯、阿拉伯聯合大公國中美洲和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和其他地區）。

細分分析：依設備類型分類，消融設備市場包括射頻設備、雷射/光消融、超音波設備、冷凍消融設備等。射頻設備細分市場在2022年佔據了相當大的市場佔有率，預計在2022年至2030年期間將呈現更高的複合年成長率。射頻消融術是一種微創手術，用於治療肌瘤、骨骼、組織、甲狀腺、子宮內膜、靜脈曲張等，可作為傳統外科手術的替代方案。

根據應用，消融器械市場細分為癌症治療、心血管疾病治療、眼科治療、婦科治療、泌尿科治療、美容手術等。心血管疾病治療領域在2022年佔據了較大的市場佔有率，預計在2022-2030年期間也將實現更高的複合年成長率。

就終端用戶而言，消融設備市場分為醫院和診所、門診手術中心和其他。 2022年，醫院和診所佔據了最大的市場佔有率，預計在2022年至2030年期間將實現最高的複合年成長率。醫院和診所是消融設備的主要終端用戶，提供廣泛的醫療服務，包括需要消融的非侵入性手術。

區域分析：從地理來看，全球消融設備市場分為五個主要區域：北美、歐洲、亞太、南美和中美以及中東和非洲。預計亞太地區在 2022 年至 2030 年期間的複合年成長率最高。印度和中國等亞太國家為消融設備市場帶來了巨大的成長潛力。該地區的發展中國家醫療基礎設施不斷改善、醫療支出不斷增加以及對先進醫療技術的日益重視，為市場成長提供了機會。隨著新興市場對醫療基礎設施的投資以及越來越多的醫生熟悉先進的消融技術，預計對消融設備的需求將會上升，從而促進亞太地區的市場成長。

2022年，北美佔據了消融設備市場的最大佔有率，其中美國佔了最大的佔有率。這一趨勢很可能從2022年持續到2030年。根據美國癌症協會的數據，2021年有超過190萬人被診斷出罹患癌症，導致608,570人死亡。此外，在美國，每2名男性中就有1名，每3名女性中就有1名可能在其一生中被診斷出罹患癌症。癌症在人群中的高盛行率推動了美國消融設備市場的成長。

美國醫療保險和醫療補助服務中心報告顯示，2021年美國全國醫療支出成長2.7%，達到4.3兆美元，人均醫療支出12,914美元。醫療支出占美國國內生產毛額（GDP）的18.3%。美國衛生與公眾服務部估計，2019年至2028年，美國全國醫療支出將以每年5.4%的速度成長，到2028年將達到6.2兆美元。醫療支出的增加可能會帶來更多藥物研發資金，從而刺激學術領域對消融設備的需求。

消融設備市場報告範圍：產業發展與未來機會：消融技術的進步大大提高了手術的有效性和安全性。新型消融設備採用射頻、微波、冷凍消融和雷射等先進技術，能夠精確破壞組織，同時最大限度地減少對周圍健康組織的傷害。這些創新提高了成功率，拓寬了消融手術的範圍，推動了市場成長。全球消融設備市場的主要參與者已採取各種舉措，包括：

全球消融設備市場的最新發展包括：

2023 年 5 月，雅培的 TactiFlex 消融導管（感測器啟用）獲得 FDA 批准，這是世界上第一個具有靈活尖端和接觸力技術的消融導管。 2023 年 2 月，Hologic Inc. 的 NovaSure V5 全球子宮內膜消融術 (GEA) 設備在加拿大和歐洲獲得醫療用途批准，具有治療各種子宮頸和子宮解剖結構的增強功能。 2021 年 11 月，美敦力印度公司推出了用於心房顫動 (AF) 治療的 Arctic Front 心臟冷凍消融導管系統，可實現微創冷凍球囊導管消融，這是治療 AF 的一種治療選擇。 2021 年 1 月，美敦力公司獲得 FDA 批准的 DiamondTemp 消融 (DTA) 系統，專為復發性、症狀性陣發性 AF 患者而設計，特別是那些對傳統藥物無反應的患者。 DTA 是首款經 FDA 批准的、採用鑽石的溫控灌注式射頻 (RF) 消融系統，目前可用於進行消融。 2020 年 12 月，Acutus Medical 在其 AcQBlate Force 消融導管和 Qubic 力感測模組獲得 CE 標誌後，在歐洲推出了 AcQBlate Force 力感測消融系統。 AcQBlate Force 是市面上唯一一款採用金頭、灌注式、力感測的射頻消融導管，整合了 Acutus Medical 與 BIOTRONIK 合作研發的先進組件。 2020 年 11 月，雅培宣布推出 IonicRF 發生器，這是一款經 FDA 批准的設備，用於以非手術、微創的方式治療神經系統疼痛。這款射頻消融設備利用熱能作用於特定神經，阻止疼痛訊號到達大腦，目前已獲准在美國和歐洲銷售。競爭格局和主要公司：消融設備市場的知名企業包括雅培實驗室、AngioDynamics Inc、AtriCure Inc、Biotronik、波士頓科學公司、Conmed Corporation、強生公司、美敦力公司、奧林巴斯公司和全錄輝公司。這些公司專注於開發新技術、改進現有產品，並拓展地理範圍以滿足日益成長的全球需求，並拓寬其特色產品組合。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：消融設備市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：消融設備市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：消融設備市場－全球市場分析

  • 消融設備 - 全球市場概覽
  • 消融設備－全球市場及2030年預測

第7章：消融設備市場-收入分析-按產品，2020-2030

  • 概述
  • 雷射/光設備
  • 射頻設備
  • 超音波設備
  • 冷凍消融設備
  • 其他

第 8 章：消融設備市場 - 收入分析 - 按應用，2020-2030 年

  • 概述
  • 癌症治療
  • 整容手術
  • 泌尿科治療
  • 心血管治療
  • 眼科治療
  • 婦科治療
  • 其他

第9章：消融設備市場-收入分析-按最終用戶，2020-2030

  • 概述
  • 醫院和診所
  • 門診手術中心（ASC）
  • 其他

第 10 章：消融設備市場 - 收入分析，2020-2030 年 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 13 章：消融設備市場 - 主要公司簡介

  • Abbott
  • Medtronic
  • Boston Scientific Corporation
  • CONMED Corporation
  • AngioDynamics
  • Smith and Nephew
  • Olympus
  • Galil Medical Inc. (Acquired by BTG International Ltd)
  • Ethicon US, LLC (subsidiary of Johnson and Johnson)
  • Stryker

第 14 章：附錄

簡介目錄
Product Code: TIPRE00003095

The ablation device market was valued at US$ 9.79 billion in 2024 and is anticipated to reach US$ 17.38 billion by 2031, with an estimated CAGR of 8.5% from 2025 to 2031.

Market Insights and Analyst View:Ablation involves the surgical excision of an organ, structure, or part. Ablation devices utilize heat (typically produced by radio frequency, RF, energy, or lasers) or extreme cold to induce minor burns. The growth of the ablation device market is primarily driven by the rising incidence of chronic diseases, an expanding elderly population, and a growing preference for minimally invasive procedures. However, the strong presence of alternative treatment options and therapies poses a challenge to market expansion.

Growth Drivers and Restraints:The increasing occurrence of chronic diseases, including cancer, cardiovascular diseases, and respiratory ailments, propels the global ablation devices market. Ablation procedures provide effective treatment alternatives for various conditions, such as tumor ablation, cardiac arrhythmias, and pulmonary issues. The World Health Organization (WHO) reports that noncommunicable diseases (NCDs) are responsible for 41 million deaths annually worldwide. Cardiovascular diseases lead NCD deaths, claiming 17.9 million lives each year, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including kidney disease deaths linked to diabetes). Additionally, the National Cancer Institute (NCI) indicates that cancer is increasingly becoming a global health concern. In 2020, over 19.3 million new cancer cases were reported, resulting in approximately 10 million cancer-related deaths globally. The WHO projects that by 2040, there could be 28.9 million new cancer cases and around 16.2 million cancer-related deaths each year. The escalating burden of chronic diseases and the demand for treatment options are driving the need for ablation devices.

Moreover, aging is a significant risk factor for chronic diseases, particularly cardiovascular issues and cancer. The Union for International Cancer Control (UICC) states that aging significantly increases cancer risk, with older adults showing a higher incidence of the disease. The WHO estimates that the percentage of the global population over 60 years will nearly double from 12% to 22% between 2015 and 2050. A study published in January 2023 by NCBI predicts that the number of individuals aged 50 and older in the U.S. will reach 221.13 million by 2050, up from 137.25 million in 2020. It is expected that individuals aged 50 and above will experience at least one chronic disease, with projections indicating a 99.5% increase from 71.52 million in 2020 to 142.66 million by 2050. Additionally, around 14 million people are expected to experience multimorbidity by 2050. Ablation procedures offer minimally invasive treatment options for the elderly, who may face higher surgical risks. Thus, the growing elderly population, combined with the rising prevalence of chronic diseases, drives the expansion of the ablation devices market.

However, ablation techniques encounter competition from alternative treatment options, including surgical procedures, radiation therapy, systemic drug therapies, and other minimally invasive techniques. Healthcare providers may choose alternative treatment modalities based on factors such as effectiveness, safety, patient eligibility, cost-effectiveness, or resource availability, depending on the specific condition being treated. The presence and preference for alternative treatment options can restrict the adoption and use of ablation devices. For instance, traditional cancer treatments like surgery, chemotherapy, and radiation therapy are often favored due to high public awareness, limited adoption of advanced treatments in developing nations, and surgeons' hesitance to move away from conventional methods. Consequently, these factors hinder the growth of the ablation device market.

Strategic Insights

Report Segmentation and Scope:The global ablation device market is categorized by device type, application, and end user. In terms of device type, the market is segmented into radiofrequency devices, laser/light ablation, ultrasound devices, cryoablation devices, and others. By application, the ablation device market is divided into cancer treatment, cardiovascular disease treatment, ophthalmologic treatment, gynecological treatment, urological treatment, cosmetic surgery, and others. Regarding end users, the market is classified into hospitals and clinics, ambulatory surgical centers, and others. Geographically, the ablation device market is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The ablation device market, categorized by device type, includes radiofrequency devices, laser/light ablation, ultrasound devices, cryoablation devices, and others. The radiofrequency devices segment held a significant market share in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030. Radiofrequency ablation is a minimally invasive procedure utilized for treating myomas, bones, tissues, thyroid, endometrium, varicose veins, and more, serving as an alternative to traditional surgical operations.

By application, the ablation device market is segmented into cancer treatment, cardiovascular disease treatment, ophthalmologic treatment, gynecological treatment, urological treatment, cosmetic surgery, and others. The cardiovascular disease treatment segment held a larger market share in 2022 and is also projected to register a higher CAGR during 2022-2030.

In terms of end users, the ablation device market is divided into hospitals and clinics, ambulatory surgical centers, and others. In 2022, the hospitals and clinics segment held the largest market share and is expected to achieve the highest CAGR from 2022 to 2030. Hospitals and clinics are the primary end users of ablation devices, providing a wide range of medical services, including non-invasive procedures that require ablation.

Regional Analysis:Geographically, the global ablation device market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. Asia Pacific is projected to experience the highest CAGR from 2022 to 2030. Countries in Asia Pacific, such as India and China, present significant growth potential for the ablation devices market. Developing nations in the region, with improving healthcare infrastructure, increasing healthcare spending, and a growing focus on adopting advanced medical technologies, provide opportunities for market growth. As emerging markets invest in healthcare infrastructure and more physicians become familiar with advanced ablation techniques, the demand for ablation devices is expected to rise, enhancing market growth in Asia Pacific.

North America accounted for the largest share of the ablation device market in 2022, with the US holding the largest share of this market. This trend is likely to continue from 2022 to 2030. According to the American Cancer Society, over 1.9 million people were diagnosed with cancer in 2021, resulting in 608,570 deaths. Furthermore, 1 in 2 men and 1 in 3 women in the US are likely to be diagnosed with cancer in their lifetime. This high prevalence of cancer among the population drives the growth of the ablation device market in the US.

The US Centers for Medicare & Medicaid Services reported that national healthcare expenditure in the US rose by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the national Gross Domestic Product (GDP). The US Department of Health & Human Services estimates that national health spending will grow at an annual rate of 5.4% from 2019 to 2028, reaching US$ 6.2 trillion by 2028. An increase in healthcare spending could lead to more funding for research and development related to drugs, thereby boosting the demand for ablation devices in academic settings.

Ablation Device Market Report ScopeIndustry Developments and Future Opportunities:Technological advancements in ablation have greatly enhanced the effectiveness and safety of procedures. Newer ablation devices utilize advanced technologies such as radiofrequency, microwave, cryoablation, and laser, allowing for precise tissue destruction while minimizing damage to surrounding healthy tissues. These innovations have improved success rates and broadened the scope of ablation procedures, driving market growth. Key players in the global ablation device market have undertaken various initiatives, including:

Recent developments in the global ablation device market include:

In May 2023, Abbott received FDA approval for its TactiFlex Ablation Catheter (Sensor Enabled), marking the world's first ablation catheter with a flexible tip and contact force technology.

In February 2023, Hologic Inc.'s NovaSure V5 global endometrial ablation (GEA) device was approved for medical use in Canada and Europe, featuring enhanced capabilities for treating a wide range of cervical and uterine anatomies.

In November 2021, Medtronic India launched the Arctic Front Cardiac Cryoablation Catheter System for atrial fibrillation (AF) treatment, enabling minimally invasive cryoballoon catheter ablation, a therapeutic option for managing AF.

In January 2021, Medtronic plc received FDA approval for the DiamondTemp Ablation (DTA) system, designed for patients with recurrent, symptomatic paroxysmal AF, particularly those unresponsive to conventional drugs. The DTA is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds, currently available for delivering ablations.

In December 2020, Acutus Medical launched the AcQBlate Force Sensing Ablation System in Europe after securing the CE Mark for the AcQBlate Force ablation catheter and the Qubic Force Sensing Module. The AcQBlate Force is the only commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter on the market, integrating advanced components through Acutus Medical's partnership with BIOTRONIK.

In November 2020, Abbott announced the launch of the IonicRF Generator, an FDA-cleared device for delivering a nonsurgical, minimally invasive treatment for managing pain in the nervous system. This RF ablation device targets specific nerves using heat to block pain signals from reaching the brain, and is approved for sale in the US and Europe.

Competitive Landscape and Key Companies:Prominent players in the ablation device market include Abbott Laboratories, AngioDynamics Inc, AtriCure Inc, Biotronik, Boston Scientific Corporation, Conmed Corporation, Johnson and Johnson, Medtronic PLC, Olympus Corporation, and Smith & Nephew PLC. These companies are focused on developing new technologies, enhancing existing products, and expanding geographically to meet the growing global demand and broaden their specialty product portfolios.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Ablation Device Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Ablation Device Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Ablation Device Market - Global Market Analysis

  • 6.1 Ablation Device - Global Market Overview
  • 6.2 Ablation Device - Global Market and Forecast to 2030

7. Ablation Device Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 7.1 Overview
  • 7.2 Laser/Light Devices
  • 7.3 Radiofrequency Devices
  • 7.4 Ultrasound Devices
  • 7.5 Cryoablation Devices
  • 7.6 Others

8. Ablation Device Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 8.1 Overview
  • 8.2 Cancer Treatment
  • 8.3 Cosmetic Surgery
  • 8.4 Urological Treatment
  • 8.5 Cardiovascular Treatment
  • 8.6 Ophthalmologic Treatment
  • 8.7 Gynecological Treatment
  • 8.8 Others

9. Ablation Device Market - Revenue Analysis (USD Million) - By End Users, 2020-2030

  • 9.1 Overview
  • 9.2 Hospitals and Clinics
  • 9.3 Ambulatory Surgical Centers (ASCs)
  • 9.4 Others

10. Ablation Device Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Ablation Device Market Overview
    • 10.1.2 North America Ablation Device Market Revenue and Forecasts to 2030
    • 10.1.3 North America Ablation Device Market Revenue and Forecasts and Analysis - By Product
    • 10.1.4 North America Ablation Device Market Revenue and Forecasts and Analysis - By Application
    • 10.1.5 North America Ablation Device Market Revenue and Forecasts and Analysis - By End Users
    • 10.1.6 North America Ablation Device Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Ablation Device Market
        • 10.1.6.1.1 United States Ablation Device Market, by Product
        • 10.1.6.1.2 United States Ablation Device Market, by Application
        • 10.1.6.1.3 United States Ablation Device Market, by End Users
      • 10.1.6.2 Canada Ablation Device Market
        • 10.1.6.2.1 Canada Ablation Device Market, by Product
        • 10.1.6.2.2 Canada Ablation Device Market, by Application
        • 10.1.6.2.3 Canada Ablation Device Market, by End Users
      • 10.1.6.3 Mexico Ablation Device Market
        • 10.1.6.3.1 Mexico Ablation Device Market, by Product
        • 10.1.6.3.2 Mexico Ablation Device Market, by Application
        • 10.1.6.3.3 Mexico Ablation Device Market, by End Users
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

13. Ablation Device Market - Key Company Profiles

  • 14.1 Abbott
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Medtronic
  • 14.3 Boston Scientific Corporation
  • 14.4 CONMED Corporation
  • 14.5 AngioDynamics
  • 14.6 Smith and Nephew
  • 14.7 Olympus
  • 14.8 Galil Medical Inc. (Acquired by BTG International Ltd)
  • 14.9 Ethicon US, LLC (subsidiary of Johnson and Johnson)
  • 14.10 Stryker

14. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud